Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a hold rating in a research report released on Saturday morning.

TVRD has been the subject of several other research reports. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Barclays set a $5.00 price target on Tvardi Therapeutics and gave the stock an “equal weight” rating in a report on Monday, October 13th. Piper Sandler cut Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 13th. Cantor Fitzgerald downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Finally, BTIG Research decreased their target price on Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $55.50.

Tvardi Therapeutics Stock Performance

NASDAQ TVRD opened at $3.72 on Friday. The business’s 50 day moving average price is $4.20 and its 200-day moving average price is $15.30. Tvardi Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $43.65. The company has a market cap of $34.89 million, a P/E ratio of -0.39 and a beta of 0.14.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.24.

Institutional Trading of Tvardi Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics during the 2nd quarter valued at about $43,000. Headlands Technologies LLC acquired a new position in Tvardi Therapeutics during the 2nd quarter valued at about $80,000. New York State Common Retirement Fund purchased a new stake in Tvardi Therapeutics in the second quarter valued at about $92,000. Finally, Squarepoint Ops LLC acquired a new stake in Tvardi Therapeutics in the third quarter worth about $318,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.